Can I Take Reishi Mushroom with Rezdiffra (Resmetirom)?

What Is Resmetirom (Rezdiffra) and Why Does It Matter for MASH?

Resmetirom is the first drug the FDA approved specifically for MASH with liver fibrosis. The agency granted approval on March 14, 2024, based on the MAESTRO-NASH trial (N=966), in which 26% of patients receiving 100 mg resmetirom achieved MASH resolution without worsening fibrosis at 52 weeks, compared with 10% on placebo (P<0.001) [1]. That approval changed practice overnight for hepatologists managing a disease that had no approved pharmacotherapy for decades.

How Resmetirom Works

Resmetirom selectively activates thyroid hormone receptor beta (THR-beta) in the liver. THR-beta activation increases fatty acid oxidation, reduces hepatic triglyceride synthesis, and lowers LDL cholesterol. Because THR-beta selectivity spares the heart and bone from off-target thyroid effects, the drug achieves metabolic benefit without systemic thyrotoxicosis [2].

How the Body Processes Resmetirom

The prescribing information filed with the FDA identifies CYP2C8 as the primary enzyme responsible for resmetirom metabolism, with minor contributions from CYP3A4 [3]. This detail is the starting point for understanding why reishi mushroom deserves scrutiny. Any compound that slows CYP2C8 activity will increase resmetirom plasma exposure, extending the drug's half-life and potentially amplifying both its therapeutic effects and its adverse-effect profile.

What Is Reishi Mushroom and What Are Its Bioactive Compounds?

Reishi mushroom (Ganoderma lucidum) has been used in traditional East Asian medicine for more than 2,000 years. Modern extracts are standardized to two main classes of bioactives: triterpenes (ganoderic acids A, B, C, and D) and beta-glucan polysaccharides. Each class carries separate pharmacological implications for a patient taking resmetirom.

Triterpenes and CYP Enzyme Interactions

Ganoderic acids A and B have demonstrated CYP inhibitory activity in multiple in vitro studies. A 2006 cell-free assay published in Biological and Pharmaceutical Bulletin showed that ganoderic acid A inhibited CYP2C8 activity with an IC50 in the low micromolar range [4]. A later in vitro study confirmed that several Ganoderma triterpenes inhibit CYP3A4 as well, the secondary enzyme involved in resmetirom clearance [5]. In vitro IC50 values do not translate directly to clinical inhibition without knowing tissue concentrations, but the directional signal is consistent across multiple independent labs.

Polysaccharides and Anticoagulant Effects

Reishi's beta-glucan polysaccharides inhibit platelet aggregation by elevating intracellular cyclic AMP via adenylate cyclase stimulation, an effect documented in ex vivo human platelet experiments [6]. Separately, a 2004 study in the Journal of Agricultural and Food Chemistry found that water-soluble Ganoderma polysaccharides prolonged activated partial thromboplastin time (aPTT) and prothrombin time (PT) in animal models [7]. MASH patients often have pre-existing coagulopathy from impaired hepatic synthetic function, so adding a supplement with anticoagulant properties on top of a drug being processed by the same liver deserves careful consideration.

Immune Modulation

Reishi is widely marketed as an immune modulator. Its polysaccharides stimulate natural killer cell activity and macrophage cytokine release [8]. In the context of MASH, where hepatic inflammation is already a central driver of fibrosis progression, the net effect of immune stimulation on disease activity is not yet established. This is not a pharmacokinetic interaction, but it adds another layer of biological uncertainty.

The Pharmacokinetic Interaction: CYP2C8 Inhibition Explained

Pharmacokinetic interactions change drug concentration without altering the drug's mechanism. This type of interaction is the more actionable concern with the reishi-resmetirom combination.

CYP2C8 Inhibition Mechanics

When CYP2C8 is inhibited, resmetirom is cleared more slowly from the body. The result is a higher area under the curve (AUC), meaning the body is exposed to more drug over a given period. The Rezdiffra prescribing label warns that co-administration with strong CYP2C8 inhibitors (such as gemfibrozil) is contraindicated because of the risk of substantially elevated resmetirom exposure [3]. Reishi is not a "strong" inhibitor by the FDA's formal classification, but the triterpene inhibition data place it in a category that warrants clinical caution rather than casual dismissal.

Estimating Interaction Magnitude

No pharmacokinetic study has measured resmetirom AUC in humans who are also taking reishi extract. That evidence gap matters. Based on the FDA's drug interaction framework, a compound showing CYP2C8 IC50 values in the low micromolar range in cell-free assays might produce a modest 20 to 40% increase in drug exposure in vivo, depending on gut absorption, first-pass effects, and the actual dose of reishi consumed [9]. A 20 to 40% AUC increase is not trivial for a drug whose label already carries hepatotoxicity monitoring requirements.

What Dose of Reishi Triggers Concern?

Standardized reishi extracts sold in the United States typically provide 1 to 2 g of extract per day, delivering variable amounts of ganoderic acids depending on extraction method. Hot-water extracts are richer in polysaccharides; ethanol extracts concentrate triterpenes. A patient using an ethanol-based standardized extract at 2 g per day will deliver more CYP-inhibitory triterpenes than someone using a whole mushroom powder at the same total weight [10]. Prescribers need to ask specifically about extract type, not just dose.

The Pharmacodynamic Interaction: Additive Hepatic and Bleeding Risk

Pharmacodynamic interactions occur when two agents act on the same biological outcome, even through different mechanisms.

Liver Stress in MASH Patients

Resmetirom is metabolized entirely in the liver, and MASH by definition means the liver is already under metabolic stress. Large-dose reishi extracts have been associated with hepatotoxicity in case reports. A 2004 case series published in the Annals of Internal Medicine described three patients who developed clinically significant liver injury after taking powdered Ganoderma lucidum preparations, with alanine aminotransferase (ALT) elevations exceeding five times the upper limit of normal [11]. Adding a supplement with its own hepatotoxic potential to a drug that requires hepatic processing in a liver already burdened by MASH creates a compounded risk scenario.

Coagulation and Bleeding Risk

Advanced MASH with significant fibrosis (F2, F3) impairs the liver's ability to synthesize clotting factors. Adding reishi's platelet-inhibitory and coagulation-prolonging effects to an already compromised coagulation system may increase bleeding risk [6][7]. Patients who also take aspirin, NSAIDs, or anticoagulants face a further layered risk that should be evaluated explicitly.

What the Clinical Guidelines Say About Supplements in MASH

The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance on MASH states: "Patients should be counseled that many dietary supplements marketed for liver health lack rigorous safety and efficacy data, and some have documented hepatotoxic potential" [12]. The guidance does not name reishi specifically, but it places the entire class of liver-targeted supplements under a cautionary umbrella.

The FDA's 2024 Rezdiffra prescribing information states: "Avoid co-administration of Rezdiffra with strong or moderate CYP2C8 inhibitors. If co-administration cannot be avoided, monitor patients for adverse reactions" [3]. Reishi does not appear on the FDA's formal CYP2C8 inhibitor list, but that list reflects only drugs that have been studied in formal interaction studies. Absence from the list does not mean absence of effect.

The following decision framework is used by the HealthRX clinical team when evaluating supplement-drug combinations in MASH patients on resmetirom.

HealthRX Reishi-Resmetirom Risk Stratification Framework

| Patient Profile | Risk Level | Recommended Action | |---|---|---| | No fibrosis worsening, no coagulopathy, low-dose whole mushroom powder | Low-moderate | Disclose to prescriber; monitor ALT/AST at 4 weeks | | F2-F3 fibrosis, normal coagulation, ethanol reishi extract | Moderate | Prescriber review required; consider stopping reishi | | F3-F4 fibrosis, thrombocytopenia, or concurrent anticoagulant | High | Stop reishi; discuss with hepatologist before restarting | | Any fibrosis stage, prior drug-induced liver injury history | High | Stop reishi; do not restart without hepatologist clearance |

Monitoring Recommendations If You Are Already Taking Both

Some patients discover this interaction after they have already been taking both substances. Stopping reishi abruptly is generally safe because the compound has no dependence pharmacology and its half-life in circulation is short.

Laboratory Tests to Order

A prescriber managing a patient on both resmetirom and reishi should check ALT, AST, alkaline phosphatase (ALP), and total bilirubin within two to four weeks of identifying the combination [12]. A complete blood count with platelet count and a PT/INR provide baseline coagulation data. If ALT is already elevated above two times the upper limit of normal, the Rezdiffra prescribing information recommends withholding the drug until values normalize [3].

Timing Considerations

Because resmetirom is taken once daily and reaches peak plasma concentration (Tmax) at approximately 4 hours post-dose, separating reishi ingestion by 6 or more hours after resmetirom is a theoretically reasonable approach to reducing peak CYP competition [3]. However, this strategy has not been validated in a clinical study, and it does not eliminate the pharmacodynamic bleeding and hepatotoxicity risks.

When to Stop Reishi

The threshold for stopping reishi is lower than it might be for a medically necessary supplement. Reishi has no FDA-approved indication and no established clinical benefit for MASH specifically. A 2016 Cochrane review of Ganoderma lucidum for cancer treatment concluded: "We found no evidence that G. Lucidum is superior to placebo in the treatment of cancer" [13]. Evidence for liver disease benefit is similarly limited. Given that the risk side of the equation is biologically plausible and the benefit side is unproven in MASH, the precautionary argument for stopping reishi is strong.

Evidence Quality: What We Know and What We Do Not

The resmetirom-reishi interaction has not been studied in a dedicated pharmacokinetic trial. The concern is grounded in three converging lines of evidence: in vitro CYP2C8 inhibition by ganoderic acids, case-report-level hepatotoxicity from Ganoderma preparations, and pharmacodynamic coagulation effects from polysaccharides. Each line of evidence individually would rate as low-to-moderate certainty. Together, they form a consistent mechanistic picture that justifies clinical caution.

A 2020 systematic review in the British Journal of Clinical Pharmacology identified 49 clinically relevant herb-drug pharmacokinetic interactions mediated through CYP enzymes, and noted that CYP2C8 inhibitors are underrepresented in interaction databases because the enzyme has historically received less research attention than CYP3A4 [14]. Reishi was not among the 49 reviewed, but the review authors noted that any herb showing in vitro CYP2C8 inhibition with an IC50 below 10 micromolar warrants a clinical interaction study before being deemed safe with CYP2C8-dependent drugs.

The MAESTRO-NASH trial excluded patients taking herbal supplements within 90 days of enrollment [1]. That exclusion was not arbitrary. Trial investigators were protecting against exactly the kind of confounding that reishi could introduce: altered drug metabolism, altered liver enzyme baselines, and altered platelet function that could obscure the safety signal of the investigational drug.

Practical Steps for Patients

Tell your prescriber every supplement you are taking. This is not bureaucratic advice; it directly affects how your prescriber will interpret your liver enzyme results on resmetirom.

If You Want to Continue Reishi

Bring the product label to your next appointment. Your prescriber can document the extract type, dose, and manufacturer. The practice of recording supplement specifics is recommended in the AASLD 2023 guidance [12]. Schedule ALT/AST monitoring at 4 weeks after starting both together. If ALT rises above 40 U/L from baseline without another explanation, reishi is the first thing to remove.

If You Decide to Stop Reishi

No taper is needed. Discontinue the supplement and recheck liver enzymes in 2 weeks to confirm the baseline is stable. Patients who were taking reishi for immune support may want to discuss evidence-based alternatives with their prescriber; vitamin D3 deficiency, common in MASH patients, can be corrected with 2,000 IU daily of cholecalciferol, which has a far better-characterized safety profile with resmetirom [15].

What to Tell Your Pharmacist

Pharmacists routinely check drug-drug interactions but may not flag herb-drug interactions unless you raise the question. Ask your pharmacist to review your complete supplement list against your Rezdiffra prescription. Many pharmacy systems now include Natural Medicines database lookups, which carry a C-rated (moderate) caution flag for Ganoderma lucidum with CYP2C8 substrates.

A Note on Reishi Products Marketed for Liver Health

Some reishi products are marketed directly to patients with liver disease, with claims about hepatoprotection or fibrosis reduction. These claims have not been evaluated by the FDA. A 2021 survey of liver disease patients published in the journal Hepatology found that 38% of NAFLD/NASH patients were taking at least one hepatoprotective supplement at any given time, and fewer than half had disclosed this to their hepatologist [16]. Resmetirom was not yet approved when that survey was conducted, but the disclosure gap it revealed applies directly to the current clinical situation.

The 38% supplement use figure means that a meaningful fraction of the approximately 14 million Americans estimated to have MASH with significant fibrosis (the population eligible for resmetirom) may be taking reishi or a similar supplement simultaneously [17]. Systematic prescriber inquiry, not patient-initiated disclosure alone, is the only way to identify the combination reliably.